Hospital Level (Tertiary and Quaternary) Essential Medicines List

Hospital Level (Tertiary and Quaternary) Essential Medicines List

Hospital Level (Tertiary and Quaternary) Essential Medicines List

Hospital Level (Tertiary and Quaternary) Essential Medicines List.

 

 

Type
Guides/Guidelines
Topic
Essential Medicines List
Language
English
Publisher
National Department of Health
Copyright
Copyright Reserved
Year
2022
Download
Tertiary and Quaternary Level Essential Medicine Recommendations December 2022
Cabergoline-Prolactinoma Historically Accepted Use 4N June 2022
Acitretin-Psoriasis Historically Accepted Use 4N June 2022
Dithranol-Psoriasis Historically Accepted Use 4N June 2022
Rituximab - Indolent Lymphomas Tertiary 4N June 2022
Updated - Clinical Criteria for Access to Trastuzumab v6 - December 2019
Cea of Gem vs Gem Cap - December 2018
Capgem Pancreas Summary - December 2018
Echinocandins Guideline - April 2018
Echinocandins Review - April 2018
Echinocandins Summary - April 2018
Gem Cap-resected Pancreatic CA Review NEMLC - December 2018
Historically Accepted Use List - December 2018
Rituximab Ra Review - July 2018
Statin Intermediate Dose - Forecast Budget Impact Analysis - 7 May 2018
RA Treatment Algorithm - August 2018
Portactant Beractant Review Document - April 2018
Rituximab for Ra Summary - July 2018
IVIG-ITP Summary - July 2018
Leflunomide-ra Summary - April 2018
Rituximab for Ra Guideline - August 2018
ATG Summary Induction-renal Replacement - 29 June 2017
Basiliximab Review Document - 29 June 2017
Basiliximab Summary Induction Transplant - 29 June 2017
Budget Impact Analysis Labalama One-pager
Bypassing Agents Review - December 2017
Clinical Criteria for Access to Trastuzumab - v5
Bypassing agents review - December 2017
Bypassing agents sum haemophila-inhibitors - December 2017
Bypassing Agents Sum Haemophila-inhibitors - December 2017
LAMA COPD Review - December 2017
LAMA COPD Summary - December 2017
Rvfiia_intractable Bleeding Summary - June 2017
Tacrolimus Summary High Risk - Renal Replace- 29 June 2017
CEA for Rituximab in iNHL v4
Tertiary and Quaternary Level Essential Medicine Recommendations_June 2022.pdf